Biosimilar Competition has the meaning set forth in Section 7.6.3(a).
Biosimilar Competition means, with respect to a Product in any country in a given calendar quarter, that, during such calendar quarter, (a) one or more generic products are commercially available in such country, and (b) aggregate Net Sales of such Product in such country in such calendar quarter equal [****] percent ([****]%) of the average aggregate Net Sales of the Product over the four (4) calendar quarters immediately prior to the calendar quarter in which one or more Generic Products first became commercially available in such country.
Biosimilar Competition means, on a Product-by-Product, country-by-country, and Calendar Year-by-Calendar Year basis, a Biosimilar Product with respect to such Product is being marketed and sold by a Third Party in such Calendar Year in such country.
Examples of Biosimilar Competition in a sentence
A detailed molecular analysis was conducted to investigate the copy number, structure and organisation of the inserts found in NK603 x MON810 maize.
Binding energiesThe analysis of frequently seen bimolecular configurations in AlQ3 and similar molecules prompted us to investigate the role of CH–p interaction in energetics and in charge transfer.
In some cases, the biosimilar price is 33% below the brand-name price (IMS Health, The Impact of Biosimilar Competition, June 2016, p.
Without an interchangeable designation, however, a biosimilar product must be specifically prescribed by a health care provider and even steeper in Epoetin and Filgrastim markets.”); Henry Grabowski, Biosimilar Competition: Lessons from Europe and Prospects for the US, OHE (Oct.
Defendants Entered Into Unlawful Market Division Agreements to Eliminate and Delay Biosimilar Competition in the U.S.
More Definitions of Biosimilar Competition
Biosimilar Competition means, with respect to a Licensed Product in a country in the Territory, the sale of one (1) or more Biosimilar Product(s), as applicable, with respect to such Licensed Product in such country.
Biosimilar Competition means, with respect to any country in the Licensed Territory, that any one or more Third Parties sell Biosimilar Products in such country that have, in the aggregate, achieved [**]% or more of the aggregate market share of Products and Biosimilar Products (based on data provided by IMS Health Incorporated, Fairfield, Connecticut) in any Calendar Quarter as measured on an aggregate sales basis (in unit sales), or if such data is not available, a methodology to be mutually agreed upon by the Parties for estimating the percentage of aggregate sales (in unit sales) based on market share of Biosimilar Products in such country.
Biosimilar Competition means, on a Licensed Product-by-Licensed Product, country-by-country, and Calendar Year-by-Calendar Year basis, both the following have occurred:
Biosimilar Competition means, with respect to a Biosimilar Product in a country or region in the Territory and particular Calendar Quarter following the Biosimilar Launch Quarter for such Biosimilar Product in such country or region, the decrease in the Net Sales in such country or region for the Licensed Product during the applicable Calendar Quarter, as compared to the average quarterly Net Sales of the Licensed Product in such country or region during the four Calendar Quarters immediately preceding such Biosimilar Launch Quarter.
Biosimilar Competition shall be deemed to exist in a particular country with respect to a particular Licensed Product in a given calendar quarter if in such country from and after the first calendar quarter during which one or more Biosimilar Products (other than one or more Authorized Biosimilar Products)) in the aggregate account(s) for more than [***] percent ([***]%) of the sum of (i) the aggregate unit sales of such Licensed Product by Licensee or its Affiliates or by a sublicensee in such country, and (ii) the aggregate unit sales of such Biosimilar Product(s) in such country, as measured by a data source as reasonably agreed upon by Inhibrx and Licensee no later than the First Commercial Sale of the applicable Licensed Product. If no data is commercially available for a country, then [***]. “Authorized Biosimilar Product” means a Biosimilar Product sold by Licensee or any of its Affiliates or sublicensee or other Third Party under a license granted by Licensee or its Affiliate, or distributed under a Regulatory Approval held by Licensee or any of its Affiliates.
Biosimilar Competition has the meaning set forth in Section 6.5.4(a). *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request.
Biosimilar Competition means, on a country or other jurisdiction and Licensed Product basis, [***] of such Licensed Product sold in that country or other jurisdiction by AbbVie, its Affiliates and Sublicensees. Unless otherwise agreed by the Parties, the [***] shall be as [***] or any other [***] by the Parties;